The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
Authors:
- Austin K. MattoxAMAustin K. Mattox
- Christopher DouvilleCDChristopher Douville
- Yuxuan WangYWYuxuan Wang
- Maria PopoliMPMaria Popoli
- Janine PtakJPJanine Ptak
- Natalie SillimanNSNatalie Silliman
- Lisa DobbynLDLisa Dobbyn
- Joy SchaeferJSJoy Schaefer
- Steve LuSLSteve Lu
- Alexander H. PearlmanAPAlexander H. Pearlman
- Joshua D. CohenJCJoshua D. Cohen
- Jeanne TieJTJeanne Tie
Top Cited Papers
- 11 August 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (10) , 2166-2179
Abstract
Cell-free DNA (cfDNA) concentrations from patients with cancer are often elevated compared with those of healthy controls, but the sources of this extra cfDNA have never been determined. To address this issue, we assessed cfDNA methylation patterns in 178 patients with cancers of the colon, pancreas, lung, or ovary and 64 patients without cancer. Eighty-three of these individuals had cfDNA concentrations much greater than those generally observed in healthy subjects. The major contributor of cfDNA in all samples was leukocytes, accounting for ∼76% of cfDNA, with neutrophils predominating. This was true regardless of whether the samples were derived from patients with cancer or the total plasma cfDNA concentration. High levels of cfDNA observed in patients with cancer did not come from either neoplastic cells or surrounding normal epithelial cells from the tumor's tissue of origin. These data suggest that cancers may have a systemic effect on cell turnover or DNA clearance. Significance: The origin of excess cfDNA in patients with cancer is unknown. Using cfDNA methylation patterns, we determined that neither the tumor nor the surrounding normal tissue contributes this excess cfDNA—rather it comes from leukocytes. This finding suggests that cancers have a systemic impact on cell turnover or DNA clearance. See related commentary by Thierry and Pisareva, p. 2122. This article is featured in Selected Articles from This Issue, p. 2109Keywords
All Related Versions
Funding Information
- Lustgarden Foundation for Pancreatic Cancer Research
- The Virginia and DK Ludwig Fund for Cancer Research
- The Sol Goldman Center for Pancreatic Cancer Research
- Marcus Foundation
- John Templeton Foundation
- National Institutes of Health (GM136577)
- National Institutes of Health (CA06973)
- National Institutes of Health (GM008752)
- Hong Kong Research Grants Council Theme-Based Research Grant (T12-401/16-W and T12-403/15N)
- Innovation and Technology Commission of the Hong Kong SAR Government
This publication has 84 references indexed in Scilit:
- DNA methylation arrays as surrogate measures of cell mixture distributionBMC Bioinformatics, 2012
- Directional DNA Methylation Changes and Complex Intermediate States Accompany Lineage Specificity in the Adult Hematopoietic CompartmentMolecular Cell, 2011
- Detection and quantification of rare mutations with massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- Immunity, Inflammation, and CancerCell, 2010
- BSMAP: whole genome bisulfite sequence MAPping programBMC Bioinformatics, 2009
- The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shoresNature Genetics, 2009
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesScience, 2008
- Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer PatientsGastroenterology, 2008
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- The Human Genome Browser at UCSCGenome Research, 2002